{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:36Z","timestamp":1790262156930,"version":"4.1.0"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05523-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:56:07Z","timestamp":1783004167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered immune cells and extracellular vesicles target tumour microenvironment barriers in solid tumour immunotherapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Xiaowei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"5523_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"5523_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"5523_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"5523_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cimid.2018.12.006","volume":"63","author":"A Nicolas-Boluda","year":"2019","unstructured":"Nicolas-Boluda A, Donnadieu E. Obstacles to T cell migration in the tumor microenvironment. Comp Immunol Microbiol Infect Dis. 2019;63:22\u201330. https:\/\/doi.org\/10.1016\/j.cimid.2018.12.006.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"5523_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31:311\u201325. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008.","journal-title":"Cancer Cell"},{"key":"5523_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41423-021-00833-2","volume":"19","author":"DR Heintzman","year":"2022","unstructured":"Heintzman DR, Fisher EL, Rathmell JC. Microenvironmental influences on T cell immunity in cancer and inflammation. Cell Mol Immunol. 2022;19:316\u201326. https:\/\/doi.org\/10.1038\/s41423-021-00833-2.","journal-title":"Cell Mol Immunol"},{"key":"5523_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ceb.2017.05.006","volume":"48","author":"M Reina-Campos","year":"2017","unstructured":"Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47\u201353. https:\/\/doi.org\/10.1016\/j.ceb.2017.05.006.","journal-title":"Curr Opin Cell Biol"},{"key":"5523_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12672-026-04473-8","volume":"17","author":"Z Luo","year":"2026","unstructured":"Luo Z, Hu Q, Ren M, et al. Obstacles and improvement strategies for CAR-T cell therapy in solid tumors. Discov Oncol. 2026;17:271. https:\/\/doi.org\/10.1007\/s12672-026-04473-8.","journal-title":"Discov Oncol"},{"key":"5523_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615:507\u201316. https:\/\/doi.org\/10.1038\/s41586-023-05778-2.","journal-title":"Nature"},{"key":"5523_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discov. 2020;10:702\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0945.","journal-title":"Cancer Discov"},{"key":"5523_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334. https:\/\/doi.org\/10.1038\/s41591-022-01726-1.","journal-title":"Nat Med"},{"key":"5523_CR12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855\u201366. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003.","journal-title":"Mol Ther"},{"key":"5523_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404. https:\/\/doi.org\/10.1002\/jev2.12404.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR14","doi-asserted-by":"publisher","first-page":"eabj7002","DOI":"10.1126\/sciadv.abj7002","volume":"8","author":"S Kamerkar","year":"2022","unstructured":"Kamerkar S, Leng C, Burenkova O, et al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci Adv. 2022;8:eabj7002. https:\/\/doi.org\/10.1126\/sciadv.abj7002.","journal-title":"Sci Adv"},{"key":"5523_CR15","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri VS, Smaglo BG, Mahadevan KK, et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat Commun. 2025;16:8696. https:\/\/doi.org\/10.1038\/s41467-025-63718-2.","journal-title":"Nat Commun"},{"key":"5523_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"5523_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368. https:\/\/doi.org\/10.1038\/nri3175.","journal-title":"Nat Rev Immunol"},{"key":"5523_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4049\/jimmunol.2001203","volume":"206","author":"AT Baker","year":"2021","unstructured":"Baker AT, Abuwarwar MH, Poly L, et al. Cancer-associated fibroblasts and T cells: from mechanisms to outcomes. J Immunol. 2021;206:310\u201320. https:\/\/doi.org\/10.4049\/jimmunol.2001203.","journal-title":"J Immunol"},{"key":"5523_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442.","journal-title":"Cancer Discov"},{"key":"5523_CR20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5:915\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0563.","journal-title":"Cancer Discov"},{"key":"5523_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Trivedi R, Lin S-Y. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci. 2022;29:83. https:\/\/doi.org\/10.1186\/s12929-022-00866-3.","journal-title":"J Biomed Sci"},{"key":"5523_CR22","doi-asserted-by":"publisher","first-page":"115010","DOI":"10.1016\/j.intimp.2025.115010","volume":"161","author":"T Kouro","year":"2025","unstructured":"Kouro T, Sasada T, Imai K. Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions. Int Immunopharmacol. 2025;161:115010. https:\/\/doi.org\/10.1016\/j.intimp.2025.115010.","journal-title":"Int Immunopharmacol"},{"key":"5523_CR23","unstructured":"Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach\u2014PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/39328262\/ (accessed May 15, 2026)."},{"key":"5523_CR24","doi-asserted-by":"publisher","first-page":"1655095","DOI":"10.3389\/fimmu.2025.1655095","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao X, Zhao B, Sun Y, Liu A. CAR-exosomes derived from immune cells: an emerging nanoscale vanguard in overcoming tumor immunotherapy hurdles. Frontiers Immunol. 2025;16:1655095. https:\/\/doi.org\/10.3389\/fimmu.2025.1655095.","journal-title":"Frontiers Immunol"},{"key":"5523_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","journal-title":"Cell Rep Med"},{"key":"5523_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","volume":"11","author":"N Kwon","year":"2025","unstructured":"Kwon N, Chen YY. Overcoming solid-tumor barriers: armored CAR-T cell therapy. Trends Cancer. 2025;11:1019\u201329. https:\/\/doi.org\/10.1016\/j.trecan.2025.08.009.","journal-title":"Trends Cancer"},{"key":"5523_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"5523_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","volume":"12","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, et al. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers (Basel). 2020;12:1075. https:\/\/doi.org\/10.3390\/cancers12051075.","journal-title":"Cancers (Basel)"},{"key":"5523_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"5523_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"key":"5523_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yuan C, Zeng C, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24:52. https:\/\/doi.org\/10.1186\/s12943-025-02265-2.","journal-title":"Mol Cancer"},{"issue":"1","key":"5523_CR32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s12967-023-04575-9","volume":"21","author":"YR Li","year":"2023","unstructured":"Li YR, Fang Y, Lyu Z, Zhu Y, Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21(1):686. https:\/\/doi.org\/10.1186\/s12967-023-04575-9.","journal-title":"J Transl Med"},{"key":"5523_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217737","volume":"624","author":"H Yuan","year":"2025","unstructured":"Yuan H, Qiu Y, Mei Z, et al. Cancer stem cells and tumor-associated macrophages: interactions and therapeutic opportunities. Cancer Lett. 2025;624:217737. https:\/\/doi.org\/10.1016\/j.canlet.2025.217737.","journal-title":"Cancer Lett"},{"key":"5523_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41568-024-00760-0","volume":"25","author":"J Agudo","year":"2025","unstructured":"Agudo J, Miao Y. Stemness in solid malignancies: coping with immune attack. Nat Rev Cancer. 2025;25:27\u201340. https:\/\/doi.org\/10.1038\/s41568-024-00760-0.","journal-title":"Nat Rev Cancer"},{"key":"5523_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.phrs.2019.02.027","volume":"142","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee S, Sil PC. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharmacol Res. 2019;142:251\u201361. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.027.","journal-title":"Pharmacol Res"},{"key":"5523_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"5523_CR37","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.abc1855","volume":"371","author":"RA Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez RA, Yu W, Cabral KA, et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021;371:1166\u201371. https:\/\/doi.org\/10.1126\/science.abc1855.","journal-title":"Science"},{"key":"5523_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z.","journal-title":"Nature"},{"key":"5523_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186268","volume":"9","author":"Y Yang","year":"2024","unstructured":"Yang Y, Vedvyas Y, Alcaina Y, et al. Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. JCI Insight. 2024;9:e186268. https:\/\/doi.org\/10.1172\/jci.insight.186268.","journal-title":"JCI Insight"},{"key":"5523_CR40","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, Frankel NW, Reddy NR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378:eaba1624. https:\/\/doi.org\/10.1126\/science.aba1624.","journal-title":"Science"},{"key":"5523_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351. https:\/\/doi.org\/10.1038\/nbt.4086.","journal-title":"Nat Biotechnol"},{"key":"5523_CR42","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","journal-title":"Nat Med"},{"key":"5523_CR43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1.","journal-title":"Nat Commun"},{"key":"5523_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348. https:\/\/doi.org\/10.1038\/s41586-023-05707-3.","journal-title":"Nature"},{"key":"5523_CR45","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"key":"5523_CR46","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"5523_CR47","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"key":"5523_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"5523_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405:127\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)02462-0.","journal-title":"Lancet"},{"key":"5523_CR50","unstructured":"Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma\u2014PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/28923105\/ (accessed May 15, 2026)."},{"key":"5523_CR51","unstructured":"CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/31970285\/ (accessed May 15, 2026)."},{"key":"5523_CR52","doi-asserted-by":"publisher","first-page":"1723270","DOI":"10.3389\/fimmu.2025.1723270","volume":"16","author":"YM Yang","year":"2025","unstructured":"Yang YM, Ding YF, Hu YY, Fan F, Zhao JL. CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies. Frontiers Immunol. 2025;16:1723270. https:\/\/doi.org\/10.3389\/fimmu.2025.1723270.","journal-title":"Frontiers Immunol"},{"key":"5523_CR53","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837\u201345. https:\/\/doi.org\/10.1038\/s41416-019-0578-3.","journal-title":"Br J Cancer"},{"key":"5523_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-026-01792-9","volume":"19","author":"Y Chen","year":"2026","unstructured":"Chen Y, Zhou L, Chen X, et al. Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies. J Hematol Oncol. 2026;19:30. https:\/\/doi.org\/10.1186\/s13045-026-01792-9.","journal-title":"J Hematol Oncol"},{"key":"5523_CR55","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","volume":"9","author":"M Alrehaili","year":"2025","unstructured":"Alrehaili M, Couto PS, Khalife R, et al. CAR-macrophages in solid tumors: promise, progress, and prospects. NPJ Precis Oncol. 2025;9:382. https:\/\/doi.org\/10.1038\/s41698-025-01170-7.","journal-title":"NPJ Precis Oncol"},{"key":"5523_CR56","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s43018-025-01015-z","volume":"6","author":"O Tsahouridis","year":"2025","unstructured":"Tsahouridis O, Xu M, Song F, et al. The landscape of CAR-engineered innate immune cells for cancer immunotherapy. Nat Cancer. 2025;6:1145\u201356. https:\/\/doi.org\/10.1038\/s43018-025-01015-z.","journal-title":"Nat Cancer"},{"key":"5523_CR57","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1158\/1078-0432.CCR-25-0197","volume":"31","author":"AN Courtney","year":"2025","unstructured":"Courtney AN, Zhou X, Tian G, et al. Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells. Clin Cancer Res. 2025;31:5137\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0197.","journal-title":"Clin Cancer Res"},{"key":"5523_CR58","doi-asserted-by":"publisher","first-page":"1625426","DOI":"10.3389\/fimmu.2025.1625426","volume":"16","author":"M Niedzielska","year":"2025","unstructured":"Niedzielska M, Chalmers A, Popis MC, et al. CAR-iNKT cells: redefining the frontiers of cellular immunotherapy. Front Immunol. 2025;16:1625426. https:\/\/doi.org\/10.3389\/fimmu.2025.1625426.","journal-title":"Front Immunol"},{"key":"5523_CR59","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5:1607\u201321. https:\/\/doi.org\/10.1038\/s43018-024-00830-0.","journal-title":"Nat Cancer"},{"key":"5523_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Li Z, Zhu Y, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025;6:100804. https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","journal-title":"Med"},{"key":"5523_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Shen X, Zhu Y, et al. Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025;18:86. https:\/\/doi.org\/10.1186\/s13045-025-01736-9.","journal-title":"J Hematol Oncol"},{"key":"5523_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Hu J, Li Z, et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med. 2025;6:102321. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102321.","journal-title":"Cell Rep Med"},{"key":"5523_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101342","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang G, Chai D, et al. iNKT: a new avenue for CAR-based cancer immunotherapy. Transl Oncol. 2022;17:101342. https:\/\/doi.org\/10.1016\/j.tranon.2022.101342.","journal-title":"Transl Oncol"},{"key":"5523_CR64","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01992.","journal-title":"J Clin Oncol"},{"key":"5523_CR65","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, et al. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11:e459\u201370. https:\/\/doi.org\/10.1016\/S2352-3026(24)00077-2.","journal-title":"Lancet Haematol"},{"key":"5523_CR66","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378. https:\/\/doi.org\/10.1038\/s41591-024-03084-6.","journal-title":"Nat Med"},{"key":"5523_CR67","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","volume":"50","author":"T Schroeder","year":"2024","unstructured":"Schroeder T, Martens T, Fransecky L, et al. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med. 2024;50:1459\u201369. https:\/\/doi.org\/10.1007\/s00134-024-07576-4.","journal-title":"Intensive Care Med"},{"key":"5523_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114450","volume":"188","author":"N Bie","year":"2022","unstructured":"Bie N, Yong T, Wei Z, et al. Extracellular vesicles for improved tumor accumulation and penetration. Adv Drug Deliv Rev. 2022;188:114450. https:\/\/doi.org\/10.1016\/j.addr.2022.114450.","journal-title":"Adv Drug Deliv Rev"},{"key":"5523_CR69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-022-00410-w","volume":"21","author":"L Cheng","year":"2022","unstructured":"Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov. 2022;21:379\u201399. https:\/\/doi.org\/10.1038\/s41573-022-00410-w.","journal-title":"Nat Rev Drug Discov"},{"key":"5523_CR70","doi-asserted-by":"publisher","first-page":"1670893","DOI":"10.1080\/20013078.2019.1670893","volume":"8","author":"Y Hong","year":"2019","unstructured":"Hong Y, Kim YK, Kim GB, et al. Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity. J Extracell Vesicles. 2019;8:1670893. https:\/\/doi.org\/10.1080\/20013078.2019.1670893.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.734720","volume":"9","author":"B Claridge","year":"2021","unstructured":"Claridge B, Lozano J, Poh QH, et al. Development of extracellular vesicle therapeutics: challenges, considerations, and opportunities. Front Cell Dev Biol. 2021;9:734720. https:\/\/doi.org\/10.3389\/fcell.2021.734720.","journal-title":"Front Cell Dev Biol"},{"key":"5523_CR72","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3390\/pharmaceutics14102236","volume":"14","author":"R Du","year":"2022","unstructured":"Du R, Wang C, Zhu L, et al. Extracellular vesicles as delivery vehicles for therapeutic nucleic acids in cancer gene therapy: progress and challenges. Pharmaceutics. 2022;14:2236. https:\/\/doi.org\/10.3390\/pharmaceutics14102236.","journal-title":"Pharmaceutics"},{"key":"5523_CR73","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/bioengineering10020136","volume":"10","author":"NJ Patel","year":"2023","unstructured":"Patel NJ, Ashraf A, Chung EJ. Extracellular vesicles as regulators of the extracellular matrix. Bioengineering (Basel). 2023;10:136. https:\/\/doi.org\/10.3390\/bioengineering10020136.","journal-title":"Bioengineering (Basel)"},{"key":"5523_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102776","volume":"77","author":"S Estes","year":"2022","unstructured":"Estes S, Konstantinov K, Young JD. Manufactured extracellular vesicles as human therapeutics: challenges, advances, and opportunities. Curr Opin Biotechnol. 2022;77:102776. https:\/\/doi.org\/10.1016\/j.copbio.2022.102776.","journal-title":"Curr Opin Biotechnol"},{"key":"5523_CR75","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jcyt.2018.12.006","volume":"21","author":"E Rohde","year":"2019","unstructured":"Rohde E, Pachler K, Gimona M. Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing. Cytotherapy. 2019;21:581\u201392. https:\/\/doi.org\/10.1016\/j.jcyt.2018.12.006.","journal-title":"Cytotherapy"},{"key":"5523_CR76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-025-02312-w","volume":"10","author":"G Xu","year":"2025","unstructured":"Xu G, Jin J, Fu Z, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025;10:255. https:\/\/doi.org\/10.1038\/s41392-025-02312-w.","journal-title":"Signal Transduct Target Ther"},{"key":"5523_CR77","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/trf.17156","volume":"63","author":"JA Korchak","year":"2023","unstructured":"Korchak JA, Wiest EF, Zubair AC. How do we assess batch-to-batch consistency between extracellular vesicle products? Transfusion. 2023;63:279\u201387. https:\/\/doi.org\/10.1111\/trf.17156.","journal-title":"Transfusion"},{"key":"5523_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12510","volume":"13","author":"RR Mizenko","year":"2024","unstructured":"Mizenko RR, Feaver M, Bozkurt BT, et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024;13:e12510. https:\/\/doi.org\/10.1002\/jev2.12510.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12433","volume":"13","author":"C Fusco","year":"2024","unstructured":"Fusco C, De Rosa G, Spatocco I, et al. Extracellular vesicles as human therapeutics: a scoping review of the literature. J Extracell Vesicles. 2024;13:e12433. https:\/\/doi.org\/10.1002\/jev2.12433.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12458","volume":"13","author":"M Van Delen","year":"2024","unstructured":"Van Delen M, Derdelinckx J, Wouters K, et al. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024;13:e12458. https:\/\/doi.org\/10.1002\/jev2.12458.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/pharmaceutics16030311","volume":"16","author":"J Goo","year":"2024","unstructured":"Goo J, Lee Y, Lee J, et al. Extracellular vesicles in therapeutics: a comprehensive review on applications, challenges, and clinical progress. Pharmaceutics. 2024;16:311. https:\/\/doi.org\/10.3390\/pharmaceutics16030311.","journal-title":"Pharmaceutics"},{"key":"5523_CR82","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/pharmaceutics17080990","volume":"17","author":"N Verma","year":"2025","unstructured":"Verma N, Arora S. Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions. Pharmaceutics. 2025;17:990. https:\/\/doi.org\/10.3390\/pharmaceutics17080990.","journal-title":"Pharmaceutics"},{"key":"5523_CR83","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2019.00211","volume":"10","author":"J Rossowska","year":"2019","unstructured":"Rossowska J, Anger N, Wegierek K, et al. Antitumor potential of extracellular vesicles released by genetically modified murine colon carcinoma cells with overexpression of interleukin-12 and shRNA for TGF-\u03b21. Front Immunol. 2019;10:211. https:\/\/doi.org\/10.3389\/fimmu.2019.00211.","journal-title":"Front Immunol"},{"key":"5523_CR84","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-025-03403-w","volume":"44","author":"Z Gong","year":"2025","unstructured":"Gong Z, Cheng C, Sun C, et al. Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy. J Exp Clin Cancer Res. 2025;44:138. https:\/\/doi.org\/10.1186\/s13046-025-03403-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"5523_CR85","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buzas","year":"2023","unstructured":"Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23:236\u201350. https:\/\/doi.org\/10.1038\/s41577-022-00763-8.","journal-title":"Nat Rev Immunol"},{"key":"5523_CR86","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jconrel.2024.12.010","volume":"378","author":"Y Meng","year":"2025","unstructured":"Meng Y, Yao Z, Ke X, et al. Extracellular vesicles-based vaccines: emerging immunotherapies against cancer. J Control Release. 2025;378:438\u201359. https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.010.","journal-title":"J Control Release"},{"key":"5523_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107352","volume":"208","author":"B Spokeviciute","year":"2024","unstructured":"Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: harnessing extracellular vesicles for enhanced efficacy. Pharmacol Res. 2024;208:107352. https:\/\/doi.org\/10.1016\/j.phrs.2024.107352.","journal-title":"Pharmacol Res"},{"key":"5523_CR88","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","volume":"44","author":"S-H Zhang","year":"2024","unstructured":"Zhang S-H, Peng L-L, Chen Y-F, et al. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy. Inflamm Regen. 2024;44:45. https:\/\/doi.org\/10.1186\/s41232-024-00358-x.","journal-title":"Inflamm Regen"},{"key":"5523_CR89","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-pharmtox-010814-124630","volume":"55","author":"B Gy\u00f6rgy","year":"2015","unstructured":"Gy\u00f6rgy B, Hung ME, Breakefield XO, et al. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015;55:439\u201364. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124630.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5523_CR90","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/pharmaceutics12100980","volume":"12","author":"C Massaro","year":"2020","unstructured":"Massaro C, Sgueglia G, Frattolillo V, et al. Extracellular vesicle-based nucleic acid delivery: current advances and future perspectives in cancer therapeutic strategies. Pharmaceutics. 2020;12:980. https:\/\/doi.org\/10.3390\/pharmaceutics12100980.","journal-title":"Pharmaceutics"},{"key":"5523_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu T, Dai L-J, Wu S-Y, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14:98. https:\/\/doi.org\/10.1186\/s13045-021-01103-4.","journal-title":"J Hematol Oncol"},{"key":"5523_CR92","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41423-022-00926-6","volume":"19","author":"J Chen","year":"2022","unstructured":"Chen J, Yang J, Wang W, et al. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. Cell Mol Immunol. 2022;19:1290\u2013301. https:\/\/doi.org\/10.1038\/s41423-022-00926-6.","journal-title":"Cell Mol Immunol"},{"key":"5523_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215668","volume":"536","author":"X Zhu","year":"2022","unstructured":"Zhu X, Hu H, Xiao Y, et al. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. Cancer Lett. 2022;536:215668. https:\/\/doi.org\/10.1016\/j.canlet.2022.215668.","journal-title":"Cancer Lett"},{"key":"5523_CR94","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","volume":"15","author":"L-Z Zhang","year":"2024","unstructured":"Zhang L-Z, Yang J-G, Chen G-L, et al. PD-1\/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression. Nat Commun. 2024;15:3884. https:\/\/doi.org\/10.1038\/s41467-024-48200-9.","journal-title":"Nat Commun"},{"key":"5523_CR95","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1016\/j.ymthe.2025.05.038","volume":"33","author":"E Coleborn","year":"2025","unstructured":"Coleborn E, Ghebosu R, Wolfram J, et al. Cancer-derived extracellular vesicles in natural killer cell immune evasion: molecular mechanisms and therapeutic insights. Mol Ther. 2025;33:4113\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.038.","journal-title":"Mol Ther"},{"key":"5523_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1071008","volume":"5","author":"B Besse","year":"2016","unstructured":"Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008. https:\/\/doi.org\/10.1080\/2162402X.2015.1071008.","journal-title":"Oncoimmunology"},{"key":"5523_CR97","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498\u2013503. https:\/\/doi.org\/10.1038\/nature22341.","journal-title":"Nature"},{"key":"5523_CR98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-3-10","volume":"3","author":"B Escudier","year":"2005","unstructured":"Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3:10. https:\/\/doi.org\/10.1186\/1479-5876-3-10.","journal-title":"J Transl Med"},{"key":"5523_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301010","volume":"12","author":"A Ghodasara","year":"2023","unstructured":"Ghodasara A, Raza A, Wolfram J, et al. Clinical translation of extracellular vesicles. Adv Healthc Mater. 2023;12:e2301010. https:\/\/doi.org\/10.1002\/adhm.202301010.","journal-title":"Adv Healthc Mater"},{"key":"5523_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12033","volume":"10","author":"VVT Nguyen","year":"2020","unstructured":"Nguyen VVT, Witwer KW, Verhaar MC, et al. Functional assays to assess the therapeutic potential of extracellular vesicles. J Extracell Vesicles. 2020;10:e12033. https:\/\/doi.org\/10.1002\/jev2.12033.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR101","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/sctm.17-0055","volume":"6","author":"AT Reiner","year":"2017","unstructured":"Reiner AT, Witwer KW, van Balkom BWM, et al. Concise review: developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl Med. 2017;6:1730\u20139. https:\/\/doi.org\/10.1002\/sctm.17-0055.","journal-title":"Stem Cells Transl Med"},{"key":"5523_CR102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12964-025-02632-y","volume":"24","author":"S Torabi","year":"2025","unstructured":"Torabi S, Yekzaman E, Taherkhani S, et al. Immune cell-based therapies for solid tumors, current challenges and therapeutic advances. Cell Commun Signal. 2025;24:73. https:\/\/doi.org\/10.1186\/s12964-025-02632-y.","journal-title":"Cell Commun Signal"},{"key":"5523_CR103","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/CCO.0000000000001152","volume":"37","author":"M Dupont","year":"2025","unstructured":"Dupont M, de Bernardi A, Vanacker H, et al. Cellular therapies in sarcoma and other solid tumors. Curr Opin Oncol. 2025;37:365\u201371. https:\/\/doi.org\/10.1097\/CCO.0000000000001152.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"5523_CR104","doi-asserted-by":"publisher","first-page":"e70011","DOI":"10.1002\/jex2.70011","volume":"3","author":"O Bar","year":"2024","unstructured":"Bar O, Porgador A, Cooks T. Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach. J Extracellular Biol. 2024;3(9):e70011. https:\/\/doi.org\/10.1002\/jex2.70011.","journal-title":"J Extracellular Biol"},{"key":"5523_CR105","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, Huang W, Heczey A, et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res. 2019;25:7126\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0421.","journal-title":"Clin Cancer Res"},{"key":"5523_CR106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2517786122","volume":"122","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Shen X, Zhu E, et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Proc Natl Acad Sci U S A. 2025;122:e2517786122. https:\/\/doi.org\/10.1073\/pnas.2517786122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5523_CR107","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo J, Guo M, Huang M, et al. Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct Target Ther. 2025;10:78. https:\/\/doi.org\/10.1038\/s41392-025-02158-2.","journal-title":"Signal Transduct Target Ther"},{"key":"5523_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114480","volume":"189","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Li J, Xiang J, et al. Transcytosis-enabled active extravasation of tumor nanomedicine. Adv Drug Deliv Rev. 2022;189:114480. https:\/\/doi.org\/10.1016\/j.addr.2022.114480.","journal-title":"Adv Drug Deliv Rev"},{"key":"5523_CR109","unstructured":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/35434273\/ (accessed May 15, 2026)."},{"key":"5523_CR110","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531\u201350. https:\/\/doi.org\/10.1038\/s41573-021-00189-2.","journal-title":"Nat Rev Drug Discov"},{"key":"5523_CR111","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1038\/s41591-023-02596-x","volume":"29","author":"AN Abou Tayoun","year":"2023","unstructured":"Abou Tayoun AN, Alsheikh-Ali A. A rapid whole-genome sequencing service for infants with rare diseases in the United Arab Emirates. Nat Med. 2023;29:2979\u201380. https:\/\/doi.org\/10.1038\/s41591-023-02596-x.","journal-title":"Nat Med"},{"key":"5523_CR112","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, Woodcock MG, Barragan G, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15:89. https:\/\/doi.org\/10.1038\/s41467-023-44310-y.","journal-title":"Nat Commun"},{"key":"5523_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jare.2021.01.001","volume":"31","author":"N Parada","year":"2021","unstructured":"Parada N, Romero-Trujillo A, Georges N, et al. Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J Adv Res. 2021;31:61\u201374. https:\/\/doi.org\/10.1016\/j.jare.2021.01.001.","journal-title":"J Adv Res"},{"key":"5523_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12085","volume":"10","author":"M Kang","year":"2021","unstructured":"Kang M, Jordan V, Blenkiron C, et al. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021;10:e12085. https:\/\/doi.org\/10.1002\/jev2.12085.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2025.103810","volume":"6","author":"Y Fang","year":"2025","unstructured":"Fang Y, Chen Y, Zhu Y, et al. Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR Protoc. 2025;6:103810. https:\/\/doi.org\/10.1016\/j.xpro.2025.103810.","journal-title":"STAR Protoc"},{"key":"5523_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202403199","volume":"36","author":"Y Xia","year":"2024","unstructured":"Xia Y, Zhang J, Liu G, et al. Immunogenicity of Extracellular Vesicles. Adv Mater. 2024;36:e2403199. https:\/\/doi.org\/10.1002\/adma.202403199.","journal-title":"Adv Mater"},{"key":"5523_CR117","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.immuni.2024.07.009","volume":"57","author":"R Kalluri","year":"2024","unstructured":"Kalluri R. The biology and function of extracellular vesicles in immune response and immunity. Immunity. 2024;57:1752\u201368. https:\/\/doi.org\/10.1016\/j.immuni.2024.07.009.","journal-title":"Immunity"},{"key":"5523_CR118","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, et al. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903. https:\/\/doi.org\/10.1084\/jem.20230903.","journal-title":"J Exp Med"},{"key":"5523_CR119","doi-asserted-by":"publisher","first-page":"1335932","DOI":"10.3389\/fimmu.2024.1335932","volume":"15","author":"T Hood","year":"2024","unstructured":"Hood T, Slingsby F, Sandner V, et al. A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors. Front Immunol. 2024;15:1335932. https:\/\/doi.org\/10.3389\/fimmu.2024.1335932.","journal-title":"Front Immunol"},{"key":"5523_CR120","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Halladay T, et al. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;25:725\u201344. https:\/\/doi.org\/10.1038\/s41577-025-01174-1.","journal-title":"Nat Rev Immunol"},{"key":"5523_CR121","doi-asserted-by":"publisher","first-page":"1759796","DOI":"10.3389\/fonc.2025.1759796","volume":"15","author":"T Ren","year":"2025","unstructured":"Ren T, Wang F, Liu X, et al. Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application. Front Oncol. 2025;15:1759796. https:\/\/doi.org\/10.3389\/fonc.2025.1759796.","journal-title":"Front Oncol"},{"issue":"7","key":"5523_CR122","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s43018-025-01015-z","volume":"6","author":"O Tsahouridis","year":"2025","unstructured":"Tsahouridis O, Xu M, Song F, Savoldo B, Dotti G. The landscape of CAR-engineered innate immune cells for cancer immunotherapy. Nat Cancer. 2025;6(7):1145\u201356. https:\/\/doi.org\/10.1038\/s43018-025-01015-z.","journal-title":"Nat Cancer"},{"key":"5523_CR123","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.7150\/thno.131621","volume":"16","author":"J Zhang","year":"2026","unstructured":"Zhang J, Pan Y, She P, et al. From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics. Theranostics. 2026;16:5044\u201364. https:\/\/doi.org\/10.7150\/thno.131621.","journal-title":"Theranostics"},{"key":"5523_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70132","volume":"14","author":"A Hassanzadeh-Barforoushi","year":"2025","unstructured":"Hassanzadeh-Barforoushi A, Sango X, Johnston EL, et al. Microfluidic devices for manufacture of therapeutic extracellular vesicles: advances and opportunities. J Extracell Vesicles. 2025;14:e70132. https:\/\/doi.org\/10.1002\/jev2.70132.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR125","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jconrel.2021.05.001","volume":"334","author":"SE Emam","year":"2021","unstructured":"Emam SE, Elsadek NE, Abu Lila AS, et al. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. J Control Release. 2021;334:327\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.001.","journal-title":"J Control Release"},{"key":"5523_CR126","doi-asserted-by":"publisher","first-page":"1755751","DOI":"10.3389\/fimmu.2026.1755751","volume":"17","author":"Y Wang","year":"2026","unstructured":"Wang Y, Zhang B, Wang Y, et al. T cell immunotherapy for solid tumors: limitations, progress, and future prospects. Front Immunol. 2026;17:1755751. https:\/\/doi.org\/10.3389\/fimmu.2026.1755751.","journal-title":"Front Immunol"},{"key":"5523_CR127","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-026-04313-9","author":"L Mao","year":"2026","unstructured":"Mao L, Ding L, Ding Y. Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies. Clin Transl Oncol. 2026. https:\/\/doi.org\/10.1007\/s12094-026-04313-9.","journal-title":"Clin Transl Oncol"},{"key":"5523_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202521913","volume":"13","author":"DJ Lundy","year":"2026","unstructured":"Lundy DJ, Chau ZL, Chen S-Y, et al. Beyond extracellular vesicle (EV) hype: practical solutions and remaining hurdles in EV research, manufacturing, and clinical translation. Adv Sci (Weinh). 2026;13:e21913. https:\/\/doi.org\/10.1002\/advs.202521913.","journal-title":"Adv Sci (Weinh)"},{"key":"5523_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04404-3","author":"Y Hong","year":"2026","unstructured":"Hong Y, Hu S, Yu Z, et al. Surface engineering of extracellular vesicles: trends, strategies, and applications in diagnosis and therapy. J Nanobiotechnol. 2026. https:\/\/doi.org\/10.1186\/s12951-026-04404-3.","journal-title":"J Nanobiotechnol"},{"key":"5523_CR130","doi-asserted-by":"publisher","first-page":"10246","DOI":"10.1021\/acsami.4c20275","volume":"17","author":"Y Song","year":"2025","unstructured":"Song Y, Wang Y, Man J, et al. Chimeric antigen receptor cells solid tumor immunotherapy assisted by biomaterials tools. ACS Appl Mater Interfaces. 2025;17:10246\u201364. https:\/\/doi.org\/10.1021\/acsami.4c20275.","journal-title":"ACS Appl Mater Interfaces"},{"key":"5523_CR131","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41419-024-06494-z","volume":"15","author":"C Lyu","year":"2024","unstructured":"Lyu C, Sun H, Sun Z, et al. Roles of exosomes in immunotherapy for solid cancers. Cell Death Dis. 2024;15:106. https:\/\/doi.org\/10.1038\/s41419-024-06494-z.","journal-title":"Cell Death Dis"},{"key":"5523_CR132","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4049\/jimmunol.1701041","volume":"200","author":"A Sugiura","year":"2018","unstructured":"Sugiura A, Rathmell JC. Metabolic barriers to T cell function in tumors. J Immunol. 2018;200:400\u20137. https:\/\/doi.org\/10.4049\/jimmunol.1701041.","journal-title":"J Immunol"},{"key":"5523_CR133","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cells15010070","volume":"15","author":"A T\u00eerziu","year":"2025","unstructured":"T\u00eerziu A, Bojin FM, Gavriliuc OI, et al. From CAR-T cells to exosome-based immunotherapy: exploring the frontiers of cell-free targeted cancer therapeutics. Cells. 2025;15:70. https:\/\/doi.org\/10.3390\/cells15010070.","journal-title":"Cells"},{"key":"5523_CR134","doi-asserted-by":"publisher","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR Stadler","year":"2024","unstructured":"Stadler CR, Ellinghaus U, Fischer L, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med. 2024;16:eadl2720. https:\/\/doi.org\/10.1126\/scitranslmed.adl2720.","journal-title":"Sci Transl Med"},{"key":"5523_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104262","volume":"360","author":"P Yang","year":"2021","unstructured":"Yang P, Cao X, Cai H, et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol. 2021;360:104262. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104262.","journal-title":"Cell Immunol"},{"key":"5523_CR136","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15:174. https:\/\/doi.org\/10.1186\/s13287-024-03783-4.","journal-title":"Stem Cell Res Ther"},{"key":"5523_CR137","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/1750743X.2025.2552105","volume":"17","author":"X Zhao","year":"2025","unstructured":"Zhao X, Li H, Zhao X, et al. Scalable and cost-effective CAR-T exosome therapies: challenges and future directions. Immunotherapy. 2025;17:891\u20138. https:\/\/doi.org\/10.1080\/1750743X.2025.2552105.","journal-title":"Immunotherapy"},{"key":"5523_CR138","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12951-026-04242-3","volume":"24","author":"R Wang","year":"2026","unstructured":"Wang R, Fu G, Dou H, et al. Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer. J Nanobiotechnol. 2026;24:388. https:\/\/doi.org\/10.1186\/s12951-026-04242-3.","journal-title":"J Nanobiotechnol"},{"key":"5523_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114425","volume":"389","author":"TO Hoang","year":"2026","unstructured":"Hoang TO, Zhang L, Kim SH, et al. Preclinical assessment of genetically modified exosomes for colorectal cancer immunotherapy. J Control Release. 2026;389:114425. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114425.","journal-title":"J Control Release"},{"key":"5523_CR140","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, et al. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019.","journal-title":"Cancer Cell"},{"key":"5523_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102418","author":"JR Lindsay","year":"2025","unstructured":"Lindsay JR, Altreuter J, Alessi JV, et al. Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102418.","journal-title":"Cell Rep Med"},{"key":"5523_CR142","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders B, Zhang P, Goodwin K, et al. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response. Clin Cancer Res. 2020;26:2176\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2183.","journal-title":"Clin Cancer Res"},{"key":"5523_CR143","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1089\/hum.2021.192","volume":"32","author":"A Aharon","year":"2021","unstructured":"Aharon A, Horn G, Bar-Lev TH, et al. Extracellular vesicles derived from chimeric antigen receptor-T cells: a potential therapy for cancer. Hum Gene Ther. 2021;32:1224\u201341. https:\/\/doi.org\/10.1089\/hum.2021.192.","journal-title":"Hum Gene Ther"},{"key":"5523_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102545","volume":"7","author":"H Zhang","year":"2026","unstructured":"Zhang H, Li S, Liu C, et al. Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell Rep Med. 2026;7:102545. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102545.","journal-title":"Cell Rep Med"},{"key":"5523_CR145","doi-asserted-by":"publisher","first-page":"13959","DOI":"10.1021\/acs.jmedchem.4c00753","volume":"67","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Xu X, Fan D, et al. Advancing tumor-targeted chemo-immunotherapy: development of the CAR-M-derived exosome-drug conjugate. J Med Chem. 2024;67:13959\u201374. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00753.","journal-title":"J Med Chem"},{"key":"5523_CR146","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","volume":"33","author":"T Coradin","year":"2025","unstructured":"Coradin T, Keating AL, Barnard AR, et al. Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector. Mol Ther. 2025;33:4953\u201367. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.006.","journal-title":"Mol Ther"},{"key":"5523_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20:e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"5523_CR148","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","volume":"32","author":"N An","year":"2026","unstructured":"An N, Wang D, Zhang P, et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nat Med. 2026;32:1257\u201366. https:\/\/doi.org\/10.1038\/s41591-026-04244-6.","journal-title":"Nat Med"},{"key":"5523_CR149","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/2326-6066.CIR-25-0663","volume":"14","author":"K Bajbouj","year":"2026","unstructured":"Bajbouj K, Xiao Z, Todd L, et al. Targeted lipid nanoparticle delivery of FAP-CAR mRNA enables potent in vivo T-cell engineering against pancreatic tumors. Cancer Immunol Res. 2026;14:559\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0663.","journal-title":"Cancer Immunol Res"},{"key":"5523_CR150","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","volume":"13","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, van Diest E, Murphy DE, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025;13:e011759. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"key":"5523_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71395-y","author":"KE Ibrahim","year":"2026","unstructured":"Ibrahim KE, Mears KS, Allen PM, et al. In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-71395-y.","journal-title":"Nat Commun"},{"key":"5523_CR152","doi-asserted-by":"publisher","first-page":"eadu9790","DOI":"10.1126\/scitranslmed.adu9790","volume":"17","author":"M Ben Khelil","year":"2025","unstructured":"Ben Khelil M, Arbab A, Srikanthan J, et al. CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis. Sci Transl Med. 2025;17:eadu9790. https:\/\/doi.org\/10.1126\/scitranslmed.adu9790.","journal-title":"Sci Transl Med"},{"key":"5523_CR153","doi-asserted-by":"publisher","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","volume":"13","author":"M Jan","year":"2021","unstructured":"Jan M, Scarf\u00f2 I, Larson RC, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021;13:eabb6295. https:\/\/doi.org\/10.1126\/scitranslmed.abb6295.","journal-title":"Sci Transl Med"},{"key":"5523_CR154","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","journal-title":"Front Pharmacol"},{"key":"5523_CR155","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/ijms18061190","volume":"18","author":"M Gimona","year":"2017","unstructured":"Gimona M, Pachler K, Laner-Plamberger S, et al. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci. 2017;18:1190. https:\/\/doi.org\/10.3390\/ijms18061190.","journal-title":"Int J Mol Sci"},{"key":"5523_CR156","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.3390\/ijms25126533","volume":"25","author":"A Stawarska","year":"2024","unstructured":"Stawarska A, Bamburowicz-Klimkowska M, Runden-Pran E, et al. Extracellular vesicles as next-generation diagnostics and advanced therapy medicinal products. Int J Mol Sci. 2024;25:6533. https:\/\/doi.org\/10.3390\/ijms25126533.","journal-title":"Int J Mol Sci"},{"key":"5523_CR157","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00116","volume":"8","author":"J Wang","year":"2024","unstructured":"Wang J, Yu B, Dou YN, et al. Biomarker-driven oncology trial design and subgroup characterization: challenges and potential solutions. JCO Precis Oncol. 2024;8:e2400116. https:\/\/doi.org\/10.1200\/PO.24.00116.","journal-title":"JCO Precis Oncol"},{"key":"5523_CR158","doi-asserted-by":"publisher","first-page":"1487627","DOI":"10.3389\/fbioe.2025.1487627","volume":"13","author":"Z Li","year":"2025","unstructured":"Li Z, Yan J, Li X, et al. Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research. Front Bioeng Biotechnol. 2025;13:1487627. https:\/\/doi.org\/10.3389\/fbioe.2025.1487627.","journal-title":"Front Bioeng Biotechnol"},{"key":"5523_CR159","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhu Y, Mei J, et al. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18:65. https:\/\/doi.org\/10.1186\/s13045-025-01717-y.","journal-title":"J Hematol Oncol"},{"key":"5523_CR160","doi-asserted-by":"publisher","first-page":"1340702","DOI":"10.3389\/fimmu.2024.1340702","volume":"15","author":"D Lv","year":"2024","unstructured":"Lv D, Fei Y, Chen H, et al. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment. Front Immunol. 2024;15:1340702. https:\/\/doi.org\/10.3389\/fimmu.2024.1340702.","journal-title":"Front Immunol"},{"key":"5523_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514661","volume":"12","author":"Y Li","year":"2025","unstructured":"Li Y, Huan C, Sun H, et al. Spatial transcriptomics and snRNA-seq expose CAF niches orchestrating dual stromal-immune barriers in hepatocellular carcinoma. Adv Sci (Weinh). 2025;12:e14661. https:\/\/doi.org\/10.1002\/advs.202514661.","journal-title":"Adv Sci (Weinh)"},{"key":"5523_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70171","volume":"14","author":"PJ Asif","year":"2025","unstructured":"Asif PJ, Borghuis LH, van Hooff SR, et al. Mesenchymal colorectal cancers secrete vesicles with unique cargo that can be used for liquid biopsy based diagnostics. J Extracell Vesicles. 2025;14:e70171. https:\/\/doi.org\/10.1002\/jev2.70171.","journal-title":"J Extracell Vesicles"},{"key":"5523_CR163","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s10555-025-10292-0","volume":"44","author":"XMM Zhou","year":"2025","unstructured":"Zhou XMM, D\u2019Amiano AJ, Lu C, et al. Spatial proteomics for investigating solid tumor resistance mechanisms. Cancer Metastasis Rev. 2025;44:76. https:\/\/doi.org\/10.1007\/s10555-025-10292-0.","journal-title":"Cancer Metastasis Rev"},{"key":"5523_CR164","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S583756","volume":"21","author":"M Wei","year":"2026","unstructured":"Wei M, Wang D, Xu W, et al. Exosomes as pivotal mediators of tumor-immune communication: implications for immunotherapy and liquid biopsy. Int J Nanomedicine. 2026;21:583756. https:\/\/doi.org\/10.2147\/IJN.S583756.","journal-title":"Int J Nanomedicine"},{"key":"5523_CR165","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/cancers17162639","volume":"17","author":"IP Trontzas","year":"2025","unstructured":"Trontzas IP, Syrigos KN. Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies. Cancers (Basel). 2025;17:2639. https:\/\/doi.org\/10.3390\/cancers17162639.","journal-title":"Cancers (Basel)"},{"key":"5523_CR166","doi-asserted-by":"publisher","first-page":"1622433","DOI":"10.3389\/fimmu.2025.1622433","volume":"16","author":"W-Y Zhang","year":"2025","unstructured":"Zhang W-Y, Yang L-Y, Fan X-X. CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies. Front Immunol. 2025;16:1622433. https:\/\/doi.org\/10.3389\/fimmu.2025.1622433.","journal-title":"Front Immunol"},{"key":"5523_CR167","doi-asserted-by":"publisher","first-page":"1158345","DOI":"10.3389\/fonc.2023.1158345","volume":"13","author":"M Uhlik","year":"2023","unstructured":"Uhlik M, Pointing D, Iyer S, et al. Xerna\u2122 TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. Front Oncol. 2023;13:1158345. https:\/\/doi.org\/10.3389\/fonc.2023.1158345.","journal-title":"Front Oncol"},{"key":"5523_CR168","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s42256-025-01074-y","volume":"7","author":"S Andani","year":"2025","unstructured":"Andani S, Chen B, Ficek-Pascual J, et al. Histopathology-based protein multiplex generation using deep learning. Nat Mach Intell. 2025;7:1292\u2013307. https:\/\/doi.org\/10.1038\/s42256-025-01074-y.","journal-title":"Nat Mach Intell"},{"key":"5523_CR169","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490. https:\/\/doi.org\/10.3389\/fonc.2024.1396490.","journal-title":"Front Oncol"},{"key":"5523_CR170","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, et al. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13:829\u201343. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0101.","journal-title":"Cancer Discov"},{"key":"5523_CR171","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","volume":"3","author":"A K\u00fcnkele","year":"2015","unstructured":"K\u00fcnkele A, Johnson AJ, Rolczynski LS, et al. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res. 2015;3:368\u201379. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0200.","journal-title":"Cancer Immunol Res"},{"key":"5523_CR172","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck R, Turley SJ, Akhurst RJ. TGF\u03b2 biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18:9\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0403-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"5523_CR173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004089","volume":"10","author":"RC Augustin","year":"2022","unstructured":"Augustin RC, Leone RD, Naing A, et al. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022;10:e004089. https:\/\/doi.org\/10.1136\/jitc-2021-004089.","journal-title":"J Immunother Cancer"},{"key":"5523_CR174","doi-asserted-by":"publisher","first-page":"1614325","DOI":"10.3389\/fphar.2025.1614325","volume":"16","author":"ZM Althafar","year":"2025","unstructured":"Althafar ZM. Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions. Front Pharmacol. 2025;16:1614325. https:\/\/doi.org\/10.3389\/fphar.2025.1614325.","journal-title":"Front Pharmacol"},{"key":"5523_CR175","doi-asserted-by":"crossref","unstructured":"Cao L-Y, Zhao Y, Chen Y, et al. CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. Front Immunol 2025;16:1583116. 10.3389\/fimmu.2025.1583116.","DOI":"10.3389\/fimmu.2025.1583116"},{"key":"5523_CR176","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tibtech.2024.08.007","volume":"43","author":"Y Ma","year":"2025","unstructured":"Ma Y, Dong S, Grippin AJ, et al. Engineering therapeutical extracellular vesicles for clinical translation. Trends Biotechnol. 2025;43:61\u201382. https:\/\/doi.org\/10.1016\/j.tibtech.2024.08.007.","journal-title":"Trends Biotechnol"},{"key":"5523_CR177","doi-asserted-by":"publisher","first-page":"1476737","DOI":"10.3389\/fbioe.2024.1476737","volume":"12","author":"L Ren","year":"2024","unstructured":"Ren L, Zhang D, Pang L, et al. Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges. Front Bioeng Biotechnol. 2024;12:1476737. https:\/\/doi.org\/10.3389\/fbioe.2024.1476737.","journal-title":"Front Bioeng Biotechnol"},{"key":"5523_CR178","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s11095-025-03961-w","volume":"42","author":"SR Mendonca","year":"2025","unstructured":"Mendonca SR, Bangera PD, Keerikkadu M, et al. Multifunctional engineering of exosomes for precision therapeutics: strategies for targeted delivery, barrier evasion, and clinical translation. Pharm Res. 2025;42:1931\u201352. https:\/\/doi.org\/10.1007\/s11095-025-03961-w.","journal-title":"Pharm Res"},{"key":"5523_CR179","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","volume":"26","author":"ZL Lamplugh","year":"2026","unstructured":"Lamplugh ZL, Wellhausen N, June CH, et al. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nat Rev Immunol. 2026;26:230\u201348. https:\/\/doi.org\/10.1038\/s41577-025-01229-3.","journal-title":"Nat Rev Immunol"},{"key":"5523_CR180","doi-asserted-by":"publisher","first-page":"1210164","DOI":"10.3389\/fimmu.2023.1210164","volume":"14","author":"G Mestrallet","year":"2023","unstructured":"Mestrallet G, Brown M, Bozkus CC, et al. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Front Immunol. 2023;14:1210164. https:\/\/doi.org\/10.3389\/fimmu.2023.1210164.","journal-title":"Front Immunol"},{"key":"5523_CR181","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41551-025-01475-9","volume":"10","author":"M Buckup","year":"2026","unstructured":"Buckup M, Figueiredo I, Ioannou G, et al. Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline. Nat Biomed Eng. 2026;10:517\u201331. https:\/\/doi.org\/10.1038\/s41551-025-01475-9.","journal-title":"Nat Biomed Eng"},{"key":"5523_CR182","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jadpro.2023.14.3.16","volume":"14","author":"DC Moore","year":"2023","unstructured":"Moore DC, Guinigundo AS. Biomarker-driven oncology clinical trials: novel designs in the era of precision medicine. J Adv Pract Oncol. 2023;14:9\u201313. https:\/\/doi.org\/10.6004\/jadpro.2023.14.3.16.","journal-title":"J Adv Pract Oncol"},{"key":"5523_CR183","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10585-023-10246-2","volume":"41","author":"W Liu","year":"2024","unstructured":"Liu W, Puri A, Fu D, et al. Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Clin Exp Metastasis. 2024;41:313\u201332. https:\/\/doi.org\/10.1007\/s10585-023-10246-2.","journal-title":"Clin Exp Metastasis"},{"key":"5523_CR184","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","volume":"8","author":"HL Williams","year":"2024","unstructured":"Williams HL, Frei AL, Koessler T, et al. The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. NPJ Precis Oncol. 2024;8:178. https:\/\/doi.org\/10.1038\/s41698-024-00671-1.","journal-title":"NPJ Precis Oncol"},{"key":"5523_CR185","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"W-C Hsieh","year":"2022","unstructured":"Hsieh W-C, Budiarto BR, Wang Y-F, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29:96. https:\/\/doi.org\/10.1186\/s12929-022-00879-y.","journal-title":"J Biomed Sci"},{"key":"5523_CR186","volume-title":"Advancing the Science of Cancer in Latinos","author":"EA Perez","year":"2020","unstructured":"Perez EA. Biomarkers and Precision Medicine in Oncology Practice and Clinical Trials. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos. Cham (CH): Springer; 2020."},{"key":"5523_CR187","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nbt.3525","volume":"34","author":"YY Lipsitz","year":"2016","unstructured":"Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34:393\u2013400. https:\/\/doi.org\/10.1038\/nbt.3525.","journal-title":"Nat Biotechnol"},{"key":"5523_CR188","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","volume":"4","author":"A Campbell","year":"2015","unstructured":"Campbell A, Brieva T, Raviv L, et al. Concise review: process development considerations for cell therapy. Stem Cells Transl Med. 2015;4:1155\u201363. https:\/\/doi.org\/10.5966\/sctm.2014-0294.","journal-title":"Stem Cells Transl Med"},{"key":"5523_CR189","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biom15101407","volume":"15","author":"S Smirnov","year":"2025","unstructured":"Smirnov S, Zaritsky Y, Silonov S, et al. Advancing CAR-T therapy for solid tumors: from barriers to clinical progress. Biomolecules. 2025;15:1407. https:\/\/doi.org\/10.3390\/biom15101407.","journal-title":"Biomolecules"},{"key":"5523_CR190","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-024-00599-5","volume":"12","author":"K Yang","year":"2024","unstructured":"Yang K, Lu R, Mei J, et al. The war between the immune system and the tumor - using immune biomarkers as tracers. Biomark Res. 2024;12:51. https:\/\/doi.org\/10.1186\/s40364-024-00599-5.","journal-title":"Biomark Res"},{"key":"5523_CR191","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s00277-025-06538-0","volume":"104","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Hu R, Xie X, et al. Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches. Ann Hematol. 2025;104:4305\u201317. https:\/\/doi.org\/10.1007\/s00277-025-06538-0.","journal-title":"Ann Hematol"},{"key":"5523_CR192","doi-asserted-by":"publisher","unstructured":"Hu C, Dignam JJ. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol 2019;3:PO.19.00086. https:\/\/doi.org\/10.1200\/PO.19.00086.","DOI":"10.1200\/PO.19.00086"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05523-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05523-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05523-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:03:51Z","timestamp":1790258631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05523-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":192,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5523"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05523-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1370"}}